How AbbVie Inc. will perform financially once top-seller Humira (adalimumab) faces biosimilar competition has been an underlying question during every quarterly earnings call the pharma has convened since its split from Abbott Laboratories Ltd in 2013. But now, as that day draws closer, analysts and investors are seeking specific answers.
During AbbVie’s third quarter 2022 earnings conference call on 28 October, CEO Rick Gonzalez said things are on track for...








